We are live on
!
Find out more
FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
1-Year Est. Return
44.84%
This Fund
S&P 500
This Quarter
Est. Return
+41.98%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$509M
AUM Growth
+$80.4M
(+19%)
Cap. Flow
-$84.7M
Cap. Flow
% of AUM
-16.66%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EPZM
Epizyme, Inc
EPZM
|
+$8.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
10x Genomics
TXG
|
+$84.4M |
| 2 |
Insmed
INSM
|
+$3.79M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$3.42M |
| 4 |
Regenxbio
RGNX
|
+$1.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
10x Genomics
TXG
$5.87B
| $492M | 96.63% |
5,503,528
-1,083,725
| -16% | -$84.4M |
|
|
EPZM
2
DELISTED
Epizyme, Inc
EPZM
| $13.8M | 2.72% |
862,402
+482,421
| +127% | +$8.42M |
|
|
XLRN
3
DELISTED
Acceleron Pharma
XLRN
| $3.31M | 0.65% |
34,784
| – | – |
|
|
4
Insmed
INSM
$23.2B
| – | – |
-236,547
| Closed | -$3.79M |
|
|
5
Regenxbio
RGNX
$623M
| – | – |
-47,443
| Closed | -$1.54M |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-253,698
| Closed | -$3.42M |
|
Similar funds
AG
SAM
AC
QI
TAAM
NAM
MSKCC
BRC
Foresite Capital Management II's Q2 2020 Portfolio in Review
As of Q2 2020, Foresite Capital Management II held 6 positions worth $509M, up 19% from $428M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Management II withdrew a net $84.7M in Q2 2020, closing 3 positions and reducing 1 holding. Its most notable exit was Insmed, an estimated $3.79M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.
Against the trend, Foresite Capital Management II added an estimated $8.42M to Epizyme, Inc.
- Foresite Capital Management II added most to Epizyme, Inc in Q2 2020, an estimated $8.42M increase.
- Foresite Capital Management II's biggest Q2 2020 reduction was 10x Genomics, cutting an estimated $84.4M.
- Foresite Capital Management II fully exited Insmed in Q2 2020, selling an estimated $3.79M.
- Foresite Capital Management II's ten largest holdings make up 100% of its $509M portfolio in Q2 2020.
- Foresite Capital Management II opened 0 new positions and closed 3 in Q2 2020.
- Foresite Capital Management II's portfolio value rose 19% quarter-over-quarter to $509M.
Based on Foresite Capital Management II's 13F filing for Q2 2020, filed 13 Aug 2020.